Cardiovascular and bleeding outcomes in a population‐based cohort of patients with chronic immune thrombocytopenia

Essentials Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet count. We conducted a cohort study of 3 584 chronic ITP patients from the Nordic countries. Cardiovascular events occurred across all platelet count levels. Cardiovascular or bleeding events were strong prognostic factors for all‐cause mortality.

[1]  H. Sørensen,et al.  Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for Romiplostim , 2019, EClinicalMedicine.

[2]  M. Lambert,et al.  Clinical updates in adult immune thrombocytopenia. , 2017, Blood.

[3]  Z. Gu,et al.  Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis , 2016, Scientific Reports.

[4]  F. Roudot-thoraval,et al.  Long-term complications of splenectomy in adult immune thrombocytopenia , 2016, Medicine.

[5]  H. Bøtker,et al.  Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study , 2016, BMJ Open.

[6]  M. Nørgaard,et al.  Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population‐based cohort study , 2016, British Journal of Haematology.

[7]  S. Wetten,et al.  Rate of bleeding-related episodes in adult patients with primary immune thrombocytopenia: a retrospective cohort study using a large administrative medical claims database in the US , 2016, Clinical epidemiology.

[8]  A. Newland,et al.  Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta‐analysis , 2016, European journal of haematology.

[9]  J. Zwaginga,et al.  Platelet function in adult ITP patients can be either increased or decreased, compared to healthy controls, and is associated with bleeding risk , 2016, Hematology.

[10]  D. Arnold.  Bleeding complications in immune thrombocytopenia. , 2015, Hematology. American Society of Hematology. Education Program.

[11]  G. Norman,et al.  Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review , 2015, Journal of thrombosis and haemostasis : JTH.

[12]  M. Lapeyre-Mestre,et al.  Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. , 2014, Blood.

[13]  G. Gaidano,et al.  Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment‐related risk factors , 2014, Journal of thrombosis and haemostasis : JTH.

[14]  J. Bussel,et al.  Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy , 2013, British journal of haematology.

[15]  H. Sørensen,et al.  Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population‐based cohort study , 2012, British journal of haematology.

[16]  H. Putter,et al.  Competing risks in epidemiology: possibilities and pitfalls. , 2012, International journal of epidemiology.

[17]  J. Sundquist,et al.  Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden , 2012, The Lancet.

[18]  M. Nørgaard,et al.  Risk and prognosis of adult primary immune thrombocytopenia , 2012, Expert review of hematology.

[19]  D. Jo,et al.  Clinical Implications of Elevated Antiphospholipid Antibodies in Adult Patients with Primary Immune Thrombocytopenia , 2011, The Korean journal of internal medicine.

[20]  R. White,et al.  Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. , 2011, Blood.

[21]  K. Kirito,et al.  Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial , 2011, International journal of hematology.

[22]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[23]  H. Sørensen,et al.  Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. , 2011, Blood.

[24]  Y. Tomiyama,et al.  Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review , 2011, International journal of hematology.

[25]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[26]  H. Sørensen,et al.  Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population‐based cohort study , 2011, British journal of haematology.

[27]  J. Bussel,et al.  Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study , 2011, The Lancet.

[28]  C. Enger,et al.  Comorbidities in patients with persistent or chronic immune thrombocytopenia , 2010, International journal of hematology.

[29]  J. Logie,et al.  Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database , 2010, Haematologica.

[30]  S. Vesely,et al.  The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports , 2010, American journal of hematology/oncology.

[31]  J. Logie,et al.  The incidence of idiopathic thrombocytopenic purpura among adults: a population‐based study and literature review , 2009, European journal of haematology.

[32]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[33]  P. Bierling,et al.  Antiphospholipid antibodies in adults with immune thrombocytopenic purpura , 2008, British journal of haematology.

[34]  J. Bussel,et al.  The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP , 2007, British journal of haematology.

[35]  S. Proctor,et al.  Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population‐based cohort of 245 patients , 2003, British journal of haematology.

[36]  J. Bussel,et al.  Long term follow‐up after splenectomy performed for immune thrombocytopenic purpura (ITP) , 2003, American journal of hematology.

[37]  R. Greil,et al.  Splenectomy versus medical treatment for idiopathic thrombocytopenic purpura. , 2002, American journal of surgery.

[38]  Lawrence C. Marsh.  Spline Regression Models , 2001 .

[39]  K. Schmidt,et al.  The incidence of idiopathic thrombocytopenic purpura in adults increases with age. , 1999, Blood.

[40]  G. Papa,et al.  Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. , 1995, The American journal of medicine.

[41]  J. Beer,et al.  Immune thrombocytopenia patients requiring anticoagulation--maneuvering between Scylla and Charybdis. , 2013, Seminars in hematology.

[42]  T. Barbui,et al.  High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. , 1991, Blood.

[43]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.